The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 23, 2016

Filed:

Aug. 12, 2013
Applicant:

Ablynx N.v., Zwijnaarde, BE;

Inventors:

Ann Brige, Ertvelde, BE;

Christine Labeur, Bruges, BE;

Veronique De Brabandere, Ghent, BE;

Marc Lauwereys, Haaltert, BE;

Assignee:

Ablynx N.V., Zwijnaarde, BE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/34 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 47/12 (2006.01); A61K 47/18 (2006.01);
U.S. Cl.
CPC ...
A61K 47/26 (2013.01); A61K 9/0019 (2013.01); A61K 39/39591 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); C07K 16/18 (2013.01); C07K 16/244 (2013.01); C07K 16/2866 (2013.01); C07K 16/2875 (2013.01); C07K 2317/22 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01);
Abstract

Formulations are provided that contain single variable domains with a good solubility and good stability under different storage, transportation and stress conditions. The formulations are useful as pharmaceutical formulation. The formulation comprises an aqueous carrier with a pH of 5.5 to 8.0, a buffer selected from the group consisting of histidine pH 6.0-6.5, hepes pH 7.0-8.0, MES pH 6.0, succinate pH 6.0-6.5 and acetate pH 5.5-6.0; an excipient; and/or a surfactant selected from polysorbate 80, polysorbate 20 and poloxamers. The formulation is further characterized that it has an inorganic salt concentration of 150 mM or lower.


Find Patent Forward Citations

Loading…